Development and validation of a liquid chromatography-tandem mass spectrometry method for topotecan determination in beagle dog plasma and its application in a bioequivalence study

Biomedical Chromatography

Volumn 27, Issue 11, 2013, Pages 1532-1539

  Ye, Ling ^a   Shi, Jian ^a   Wan, Shanhe ^a   Yang, Xiaoshan ^a   Wang, Ying ^a   Zhang, Jiajie ^a   Zheng, Dayong ^a   Liu, Zhongqiu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bioequivalence; Liquid chromatography tandem mass spectrometry; Topotecan

Indexed keywords

ELECTROSPRAY IONIZATION; EXTRACTION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA STABILITY; POSITIVE IONS; SIGNAL TO NOISE RATIO;

BEAGLE DOG; BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; DOG PLASMA; EXTRACTION RECOVERY; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; MATRICES EFFECT; RECOVERY EFFECTS; TOPOTECAN;

PHOSPHOLIPIDS;

CAMPTOTHECIN; GENERIC DRUG; TOPOTECAN; UNCLASSIFIED DRUG; XINZE;

ACCURACY; ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ARTICLE; BEAGLE DOG; BIOEQUIVALENCE; CALIBRATION; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DOG; DRUG CAPSULE; DRUG DETERMINATION; DRUG FORMULATION; LIQUID CHROMATOGRAPHY; LUNG SMALL CELL CANCER; MALE; MASS SPECTROMETER; NONHUMAN; PLASMA; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY;

CANIS FAMILIARIS;

BIOEQUIVALENCE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; OSTROTM SORBENT PLATE; TOPOTECAN;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; LIMIT OF DETECTION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84885941733     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2956     Document Type: Article

References (24)

1. Arellano C, Gandia P, Bettuing L, Woodley J and Chatelut E. Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2010; 878: 645-652.
2. Baczek T, Konieczna L, Belka M, Maciejka-Kapuscinska L, Wisniewski J, Niedzwiecki M, Balcerska A, Adamkiewicz-Drozynska E and Wachowiak J. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. Journal of Pharmaceutical and Biomedical Analysis 2012; 70: 330-336.
3. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RI, Lange BJ, Reaman GH, Horowitz ME, Poplack DG and Balis FM. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78: 527-531.
4. Chen J and Balthasar JP. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2005; 816: 183-192.
5. Davies BE, Minthorn EA, Dennis MJ, Rosing H and Beijnen JH. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Pharmaceutical Research 1997; 14: 1461-1465.
6. de Vries NA, Ouwehand M, Buckle T, Beijnen JH and van Tellingen O. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomedical Chromatography 2007; 21: 1191-1200.
7. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD and Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. Journal of Controlled Release 2010; 141: 13-21.
8. Evstigneev MP, Mosunov AA, Evstigneev VP, Parkes HG and Davies DB. Quantification of the interceptor action of caffeine on the in vitro biological effect of the anti-tumour agent topotecan. European Biophysics Journal 2011; 40: 969-980.
9. Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J and von Hoff DD. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. European Journal of Cancer 1998; 34: 1030-1035.
10. Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD and Verweij J. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clinical Cancer Research 1999; 5: 69-75.
11. Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH and Schellens JH. Oral topotecan: bioavailablity and effect of food co-administration. British Journal of Cancer 1999; 80: 1380-1386.
12. Hubbard KE, Schaiquevich P, Bai F, Fraga CH, Miller L, Panetta JC and Stewart CF. Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomedical Chromatography 2009; 23: 707-713.
13. Leggas M, Zhuang Y, Welden J, Self Z, Waters CM and Stewart CF. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. Journal of Pharmaceutical Science 2004; 93: 2284-2295.
14. Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC and Belasco JB. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatric Blood & Cancer 2011; 56: 39-44.
15. Motl S, Zhuang Y, Waters CM and Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clinical Pharmacokinetics 2006; 45: 871-903.
16. Park MS, Shim WS, Yim SV and Lee KT. Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2012; 902: 137-141.
17. Reddy SR, Rao Divi K, Chandiran IS, Jayaveera KN, Naidu YK and Reddy MP. Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of clopidogrel and its metabolite in human plasma. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2010; 878: 502-508.
18. Ritchie M, Mal M and Wong S. Extraction of phospholipids from plasma using ostro sample preparation. Waters website, http://www.waters.com/waters/library.htm?locale=en_US&cid=10156075&lid=134659464 2012.
19. Rosing H, Doyle E, Davies BE and Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. Journal of Chromatography. B, Biomedical Applications 1995; 668: 107-115.
20. State Food and Drug Administration. Guidance of bioavailability and bioequivalence technology research of chemical medicine preparations, website, http://www.cde.org.cn/zdyz.do?method=largePage&id=2066 2005
21. Smeraglia J, Baldrey SF and Watson D. Matrix effects and selectivity issues in LC-MS-MS. Chromatographia 2002; 55: 95-99.
22. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
23. Wheaton PJ, Chambers EE and Fountain JK. Improving the cleanlinessn of DBS extracts using the ostro 96-well sample preparation plate and single step method. Waters website, http://www.waters.com/waters/library.htm?locale=en_US&cid=10156075&lid=134632935 2011.
24. Wheaton PJ, Chambers EE and Diehl MD. A novel sample preparation device for improved phospholipid removal in bioanalytical assays. Waters website, http://www.waters.com/waters/library.htm?locale=en_US&cid=10156075&lid=10181840 2010.